ARRALYZE® Launches CellShepherd®: A Fully Autonomous Single-Cell Platform For Real-Time Monitoring Of Functional Assays
Werbung
|
Garbsen, Germany, (February 5th 2024). ARRALYZE®, the Life Science arm of LPKF Laser & Electronics SE, proudly announces the commercial availability of the CellShepherd®. After a successful beta-testing phase in 2023, this groundbreaking platform is now ready to revolutionize cell-based research and development across biomedical and various life science fields.
CellShepherd®: Redefining Single-Cell Analysis CellShepherd®, developed by ARRALYZE®, responds to the urgent need for advanced functional cell screening technologies in academic and industrial laboratories. It stands out with ARRALYZE’s proprietary nanowell glass arrays, which miniaturize cell-based assays while enabling real-time monitoring at the single-cell level. This autonomous platform boasts precise dispensing into nanoliter glass wells and supports (co)-culturing under climate-controlled, sterile conditions. Its capabilities extend to real-time imaging through a brightfield microscope and three fluorescent channels. Leveraging advanced AI-driven analysis, CellShepherd® accurately counts and tracks cells, offering vital insights into various parameters. This innovation promises a new era in scientific research characterized by precision, control, and deep insights. Meeting Market Demands: The ARRALYZE® Vision CellShepherd® is designed to fulfill the growing demand for technologies capable of studying small and large cell populations at the single-cell level and isolating target cells. By adopting a holistic approach, ARRALYZE® enables customers to uncover individual characteristics of heterogeneous cell populations and gain insight into the kinetics of experiments, monitoring functionality at different time points. This approach overcomes challenges such as harsh experiment conditions, limited microenvironment control, and difficulties maintaining cell viability. Key Features and Benefits
About LPKF LPKF Laser & Electronics SE, the parent company of ARRALYZE, is a leading provider of laser-based solutions for the technology industry. Founded in 1976, the company is headquartered in Germany, and is active worldwide through subsidiaries and representatives. The establishment of ARRALYZE as a dedicated division signifies LPKF’s commitment to innovation and excellence in the biotechnological sector. LPKF Laser & Electronics SE shares are traded in the Prime Standard segment of Deutsche Börse (ISIN 0006450000). Contact For more information about CellShepherd® and ARRALYZE®, please visit www.arralyze.com or contact us by email at info@arralyze.com ARRALYZE is part of LPKF group: LPKF Laser & Electronics SE Osteriede 7 D-30827 Garbsen Fon: +49 (0) 5131 7095-0 Fax: +49 (0) 5131 7095-90 www.lpkf.com End of Media Release Issuer: LPKF Laser & Electronics SE Key word(s): Research/Technology Werbung
05.02.2024 CET/CEST Dissemination of a Press Release, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | LPKF Laser & Electronics SE |
| Osteriede 7 | |
| 30827 Garbsen | |
| Germany | |
| Phone: | +49 (0) 5131 7095-0 |
| Fax: | +49 (0) 5131 7095-95 |
| E-mail: | investorrelations@lpkf.com |
| Internet: | www.lpkf.com |
| ISIN: | DE0006450000 |
| WKN: | 645000 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1822061 |
| End of News | EQS Media |
|
|
1822061 05.02.2024 CET/CEST
Ausgewählte Hebelprodukte auf LPKF Laser Electronics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf LPKF Laser Electronics
Der Hebel muss zwischen 2 und 20 liegen
Risikohinweis: Im Durchschnitt erleiden
7 von 10 Kleinanlegern Verluste beim Handel mit Turbo-Zertifikaten.
Turbo-Zertifikate sind hoch risikoreiche Produkte und nicht für langfristige
Anlagestrategien geeignet.
Risikohinweis: Im Durchschnitt erleiden
7 von 10 Kleinanlegern Verluste beim Handel mit Turbo-Zertifikaten.
Turbo-Zertifikate sind hoch risikoreiche Produkte und nicht für langfristige
Anlagestrategien geeignet.
Werbung Werbung